Merrimack Pharmaceuticals, Inc. MACK
Set alert
15.15 0.00 0.00%
As of May 17, 3:59 PM ET
15.14 Day range 15.17
52-week range unavailable
- Open
- 15.15
- Prev close
- 15.15
- Mkt cap
- 223.75M
- Vol
- 922.50K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 100.00%
More statistics
- Low
- 15.14
- High
- 15.17
- Forward P/E
- -8.50
- Beta
- 1.42
- Short ratio
- 8.65
- Inst. own
- 62.98%
- Dividend
- 15.10
- Ex-div date
- May 8, 2024
- Earnings
- May 15, 2024
- 50-d avg
- 14.84
- 200-d avg
- 13.48
- 1y target
- 0.00
3M chart
Events in this range
- Mar 7, 2024Earnings: —; estimate 0; surprise —%
- May 9, 2024Dividend: 15.1
- May 15, 2024Earnings: —; estimate 0; surprise —%
- May 20, 2024Dividend: 15.1
Signals (8)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 22, 2024 | 2 years ago |
| MACD: Buy Signal | May 1, 2024 | 2 years ago |
| RSI: Overbought | May 1, 2024 | 2 years ago |
| SMA: Bullish | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 12, 2024 | 2 years ago |
| SMA: Bullish | Apr 9, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 1, 2024 | 2 years ago |
| RSI: Overbought | Mar 1, 2024 | 2 years ago |
Key statistics
- Market cap
- 223.75M
- Enterprise value
- -20.36M
- Trailing P/E
- 0.00
- Forward P/E
- -8.50
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.99
- EPS (TTM)
- -0.09
- Beta
- 1.42
- Dividend yield
- 100.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 21.01M
- Total cash
- 244.11M
- Total debt
- 0
- Return on equity
- -1.12%
- Shares outstanding
- 14.79M
- Short % of float
- 8.25%
- 50-day average
- 14.84
- 200-day average
- 13.48
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
May 15, 2024
Expected May 15, 2024. Consensus EPS estimate 0.00.
Financials — quick view
MACK Revenue — quarterly 0
MACK Net income — quarterly 201.37M
MACK EPS — quarterly 13.93
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 4, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 9, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2018 | Baird | main | Neutral | Neutral |
| Jun 25, 2018 | Baird | main | Neutral | Neutral |
| Jun 24, 2018 | JP Morgan | down | Neutral | Underweight |
| Oct 6, 2016 | JP Morgan | down | Overweight | Neutral |
| Aug 18, 2016 | BTIG | init | — | Neutral |
| Aug 4, 2016 | JP Morgan | main | — | Overweight |
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- merrimack.com
News
- Mackay Gold & Silver to Acquire Comstock Inc.'s Nevada Mining Assets, Creating the Largest Consolidated Land Package in the History of the Historic Comstock Gold-Silver District
- Mackay Gold & Silver Announces Listing on the OTCQB Under the Symbol "MKGSF"
- Arthur J. Gallagher & Co. Acquires MACK Insurance Services
- Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
- Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
- Merrimack Receives $225 Million Milestone Payment from Ipsen
- Merrimack Reports Full Year 2023 Financial Results
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- Merrimack Reports Third Quarter 2023 Financial Results
- Merrimack Reports Second Quarter 2023 Financial Results
Your note
Sign in to keep a note on MACK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 22NW, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 16, 2019 | 0 |
| ANDERSEN ERIC D | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 27, 2023 | 0 |
| ARYEH JASON M | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 15, 2019 | 3,802 |
| CROCKER GARY L | President | Purchase | Aug 10, 2023 | 0 |
| DRUMMOND DARYL C | Officer | Sale | May 11, 2017 | 0 |
| JFL CAPITAL MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 1, 2019 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Newtyn Management, Llc | 13.08% | 1,873,694 | 23.05M | Jun 29, 2023 |
| Western Standard, LLC | 11.68% | 1,672,463 | 20.57M | Jun 29, 2023 |
| Blackrock Inc. | 4.72% | 676,290 | 8.32M | Jun 29, 2023 |
| Vanguard Group Inc | 3.89% | 556,798 | 6.85M | Jun 29, 2023 |
| Madison Avenue Partners, LP | 3.86% | 553,085 | 6.80M | Jun 29, 2023 |
| Dimensional Fund Advisors LP | 3.21% | 459,960 | 5.66M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 286,028 | 3.52M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.53% | 218,882 | 2.67M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.38% | 198,199 | 2.44M | Jun 29, 2023 |
| DFA U.S. Micro Cap Series | 1.04% | 148,849 | 1.79M | Jul 30, 2023 |
| DFA U.S. Small Cap Series | 0.80% | 115,240 | 1.38M | Jul 30, 2023 |
| Fidelity Small Cap Index Fund | 0.70% | 99,808 | 1.20M | Jul 30, 2023 |